Usual Adult Dose of Gleevec for Myeloproliferative Disorder: 400 mg orally once a day Comments: -Determine PDGFRb gene rearrangements status prior to initiating therapy. Use: For patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR (platelet-derived growth factor recept...
Use: Treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.Usual Adult Dose for Lymphoma:Follicular...
For TPO-R agonists there is a theoretical concern that they may stimulate the progression of existing haematopoietic malignancies such as MDS. Cataracts Cataracts were observed in toxicology studies of eltrombopag in rodents (see section 5.3). The clinical relevance of this finding is unknown. ...
In 2006, the FDA approved thalidomide for MM therapy in combination with dexamethasone. In 2005, the FDA approved the use of lenalidomide in the treatment of myelodysplastic syndrome (MDS) with 5q deletion, of MM in 2006, of either relapsed or refractory mantle cell lymphoma in 2013, as ...
Current requirements for studies of drugs for the pathogenetic treatment of multiple sclerosis 来自 Semantic Scholar 喜欢 0 阅读量: 13 作者:AN Boyko,NN Spirin,YV Vlasov,MN Zakharova 摘要: More than 10 multiple sclerosis-modifying drugs (MSMDs) are widely used now. Novel MSMDs should be ...
In an open-label, exploratory study, zuranolone 20 or 30 mg was given to 14 participants as an add-on therapy for 7 days [59], and results showed a 40% significant improvement in MDS-UPDRS Part II/III tremor total score (7.7 points) compared to baseline. The most common adverse ...
Globally, several TIM-3 antibodies are being clinically evaluated at various stages. Sabatolimab (MBG453), which was developed by Novartis and has been granted rapid review for MDS indications by the FDA, is in a phase III trial for acute myeloid leukemia (AML) and high-risk myelodysplastic ...
Histone deacetylase inhibitors, which may also impact the expression of genes through epigenetic mechanisms, seem to have measurable activity in MDS in preliminary studies. Histone deacetylase inhibitors are most likely used in combination with other agents, including DNA methyltransferase inhibitors. ...
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 1055–1066. 17 San-Miguel MD JF, Hungria VTM, Yoon MDS. Randomized phase 3 trial...
Has also been used for treatment of melanoma† [off-label], ovarian cancer† [off-label], myelodysplastic syndrome (MDS)† [off-label], advanced pancreatic cancer†, primary brain tumors† (designated an orphan drug by FDA for this use), androgen-independent prostate cancer†, and ...